

Ketotifen belongs to the group of mast cell membrane stabilizers. It inhibits the release of histamine and other mediators (including leukotrienes, cytokines) from mast cells, prevents eosinophilic infiltration in places of allergic inflammation. It has a blocking effect on (H1) histamine receptors, inhibits phosphodiesterase, blocks cell calcium channels, is a functional leukotriene antagonist.
Ketotifen is an effective oral medication for the prevention of bronchial asthma. It has a pronounced anti-anaphylactic and anti-allergic effect. When used alone, it does not stop asthma attacks, but leads to a decrease in the number, duration and intensity of these attacks. In some cases, there is a complete disappearance of attacks of bronchial asthma. The drug has a positive effect on the exposure, reduces eosinophilia, reduces the need for the use of bronchodilators, corticosteroids, etc.
Long-term prophylaxis of allergic bronchial asthma and mixed forms, allergic bronchitis, asthmatic complications of hay fever, allergic rhinitis, allergic dermatoses, migraine.
1 tablet contains 1 mg ketotifen fumarate.
Ketotifen is marketed under different brands and generic names, and comes in different dosage forms:
Brand name | Manufacturer | Country | Dosage form |
---|---|---|---|
Ketotifen pills 0,001 g | Irbit HFZ | Russia | pills |
Ketotifen pills 0,001 g | Sopharma | Bulgaria | pills |
Ketotifen | Sopharma | Bulgaria | syrup |
No customer reviews for the moment.
Ketotifen drug is taken orally. Assign adults - twice a day (morning and evening), 1 tablet (1 mg) with meals. If necessary, the daily dose can be increased to 4 mg (divided into 2 doses).
Children over 3 years old are prescribed ketotifen pills as follows: with a body weight of up to 25 kg, twice a day (in the morning and in the evening) 1/2 tablet; more than 25 kg - twice a day, 1 tablet. With insufficient therapeutic effect after 4-week treatment of children weighing less than 25 kg, the dose can be increased to 1 tablet 2 times a day.
In the first days of administration, drowsiness, dry mouth, mild dizziness, and fatigue are possible, which usually pass spontaneously. In such cases, the dose to adults is reduced to 1 mg per day.
In rare cases, thrombocytopenia, weight gain, allergic skin reactions are possible.
Pregnancy, lactation (suspend breastfeeding), increased individual sensitivity to ketotifen, children's age - up to 3 years.
It is advisable to avoid the combined use of ketotifen with oral antidiabetic agents because of possible reversible thrombocytopenia. It is also possible to potentiate the effect of sedatives, narcotic drugs and alcohol, which is why such combinations should be avoided.
In the first days of treatment, motor coordination reactions may slow down. Patients should be warned about the need to refrain from activities requiring high concentration of attention and good motor coordination, including driving vehicles.
Overdose events are observed at plasma concentrations of ketotifen 5–122 ng / ml (therapeutic concentration 1–4 ng / ml). Symptoms: weakness, disorientation, confusion, dyspnea, tachycardia or bradycardia, convulsions, severe hypotension.
Treatment: symptomatic therapy. There is no specific antidote.
Studies and clinical trials of Ketotifen (Click to expand)